Abstracts Archive - Page 940 of 2425 - ACR Meeting Abstracts

Abstract Number: 2726 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Jessica Shantha¹, Amy Cassedy ², Joseph McDonald ³, Theresa Hennard ⁴, Najima Mwase ⁵, Steven Yeh ¹ and Sheila Angeles-Han ⁶, ¹Emory University, Atlanta, GA, ²Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Uveitis is a heterogenous group of ocular inflammatory diseases. Underlying disease and treatment can lead to poor quality of life (QOL), depression, and increased…
Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Bhargavi Duvvuri¹, Lauren Pachman ², Richard Moore ¹, Gabrielle Morgan ², Marisa Klein-Gitelman ², Megan L. Curran ³, Stephen Doty ⁴ and Christian Lood ¹, ¹University of Washington, Seattle, ²Northwestern University, Chicago, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…
Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde¹, In-Ho Song ², Aileen Pangan ³, Atul Deodhar ⁴, Filip Van den Bosch ⁵, Walter P. Maksymowych ⁶, Tae-Hwan Kim ⁷, Mitsumasa Kishimoto ⁸, Andrea Everding ⁹, Yunxia Sui ¹⁰, Xin Wang ¹⁰, Alvina D. Chu ¹⁰ and Joachim Sieper ¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Oregon Health & Science University, Portland, OR, ⁵Ghent University Hospital, Ghent, Belgium, ⁶University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁹HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ¹⁰AbbVie Inc., Chicago, ¹¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
Abstract Number: 2729 • 2019 ACR/ARP Annual Meeting
Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Atul Deodhar¹, Désirée van der Heijde ², Lianne Gensler ³, Tae-Hwan Kim ⁴, Walter P. Maksymowych ⁵, Mikkel Østergaard ⁶, Denis Poddubnyy ⁷, Helena Marzo-Ortega ⁸, Louis Bessette ⁹, Tetsuya Tomita ¹⁰, Gaia Gallo ¹¹, David Adams ¹¹, Ann Leung ¹², Fangyi Zhao ¹¹, Maja Hojnik ¹¹, Hilde Carlier ¹³ and Joachim Sieper ¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³University San Francisco California, San Francisco, CA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ⁹Laval University, Quebec City, QC, Canada, ¹⁰Osaka University Graduate School of Medicine, Osaka, Japan, ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Syneos Health, Raleigh, NC, ¹³Eli Lilly and Company, Indianapolis, ¹⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Ixekizumab (IXE), a high affinity IL-17A monoclonal antibody, previously showed efficacy in AS/radiographic-axSpA1,2. COAST-X (NCT02757352) is a phase 3 study that assessed efficacy and…
Abstract Number: 2730 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Paul Miller¹, Arkadi Chines ², Ben-Hur Albergaria ³, Evelien Gielen ⁴, Bente Langdahl ⁵, Akimitsu Miyauchi ⁶, Mark Vanderkelen ⁷, Cassandra Milmont ², Judy Maddox ² and Jonathan Adachi ⁸, ¹Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of Espirito Santo, Vitória, Brazil, ⁴Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷UCB Pharma, Brussels, Belgium, ⁸McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Osteoporosis and renal insufficiency are coexisting disease states in a substantial proportion of postmenopausal women. Since bisphosphonates are generally contraindicated in patients with estimated…
Abstract Number: 2731 • 2019 ACR/ARP Annual Meeting
Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Natalie McCormick¹, Zachary Wallace ², Chana Sacks ³, John Hsu ⁴ and Hyon K. Choi ⁵, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁴Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Billions of public dollars are spent each year on biologic disease-modifying anti-rheumatic drugs (bDMARDs), but the drivers of bDMARD spending and per-patient cost increases…
Abstract Number: 2732 • 2019 ACR/ARP Annual Meeting
The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations
Ken Cai¹, Billy Wu ², Suneela Mehta ², Nicola Dalbeth ², Rod Jackson ² and Poppe Katrina ², ¹University of Auckland, Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular events. Furthermore, urate-lowering therapy such as allopurinol may be associated with…
Abstract Number: 2733 • 2019 ACR/ARP Annual Meeting
Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus
Gautam Sule¹, Kristen Gilley ¹, Andrew Fernandes ¹, Srilakshmi Yalavarthi ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Dysregulated neutrophil extracellular trap (NET) release has been proposed as a source of autoantigens in lupus. Furthermore, it has recently been shown that the…
Abstract Number: 2734 • 2019 ACR/ARP Annual Meeting
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Morgane Humbel ¹, Florence Bellanger ¹, Craig Fenwick ², Alice Horisberger ³, Camillo Ribi ³ and Denis Comte¹, ¹Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinges, Vaud, Switzerland, ²Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinhes, Vaud, Switzerland, ³Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by quantitative and qualitative deficiencies of immune cells. Natural killer (NK) cells are innate…
Abstract Number: 2735 • 2019 ACR/ARP Annual Meeting
Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis
Vinh Nguyen ¹, Alexandru Tatomir ², Horea Rus ³, Cinthia Drachenberg ¹, John Papdimitriou ¹, Tudor Badea ⁴, Irina Luzina ⁵ and Violeta Rus¹, ¹Univ of Maryland Sch of Medicine, Baltimore, MD, ²Univ of Maryland Sch of Medicine, Baltimore, ³Univ of Maryland Sch of Med and VAMHCS, Baltimore, MD, ⁴NIH, NEI, Bethesda, MD, ⁵Univ of Maryland Sch of Med AND VAMHCS, Baltimore
Background/Purpose: Response Gene to Complement (RGC)-32 is a cell cycle regulator widely expressed in normal tissues, multiple tumors and a variety of cell lines. RGC-32…
Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Goh Murayama¹, Asako Chiba ², Tomohiro Mizuno ³, Atsushi Nomura ², Taiga Kuga ⁴, HIrofumi Amano ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 2737 • 2019 ACR/ARP Annual Meeting
HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus
Barry Garchow¹ and Marianthi Kiriakidou ¹, ¹Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Hypoxia inducible factor 1 is a key transcription factor that regulates the cellular response to oxygen stress. In the adaptive immune system, HIF-1α is…
Abstract Number: 2738 • 2019 ACR/ARP Annual Meeting
Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis
Rizi Ai¹, David Boyle ², Deepa Hammaker ³, Kevin Deane ⁴, V. Michael Holers ⁵, Andre Matti ⁶, William Robinson ⁷, Jane Buckner ⁸, Navin Rao ⁹, Frédéric Baribaud ¹⁰, George Vratsanos ¹¹, Sunil Nagpal ⁹, Wei Wang ² and Gary Firestein ³, ¹University of California San Diego, San Diego, ²University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁶UCSD, La Jolla, CA, ⁷Stanford University, Stanford, CA, ⁸Benaroya Research Institute, Seattle, WA, ⁹Janssen R&D, Spring House, PA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹JNJ, Raritan, NJ
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing RA because of serum anti-citrullinated protein antibody…
Abstract Number: 2739 • 2019 ACR/ARP Annual Meeting
Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis
Mika Tabata¹, Kavita Sarin ², Karen Page ³, Christine Huard ³, Shanrong Zhao ³, Donald Bennett ³, Jillian Johnson ³, Kristen Johnson ³ and David Fiorentino ², ¹Stanford University School of Medicine, Stanford, CA, ²Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Pfizer, Boston
Background/Purpose: Interferon (IFN) signaling is upregulated in dermatomyositis (DM) and thought to play a role in pathogenesis. An IFN gene signature in peripheral blood of…
Abstract Number: 2740 • 2019 ACR/ARP Annual Meeting
Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex
Xiufang Kong ¹ and Amr Sawalha², ¹University of Michigan & Fudan University, Ann Arbor, MI, ²University of Pittsburgh & University of Michigan, Pittsburgh, PA
Background/Purpose: Previous work has revealed a genetic association between Takayasu arteritis and a non-coding genetic variant in an enhancer region within IL6 (rs2069837 A/G). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].